Morgan Stanley upgraded Novo Nordisk (NVO) to Equal Weight from Underweight with a price target of $40, down from $42. Post the selloff on the REDEFINE-4 data, Novo’s valuation better reflects its mid-term growth uncertainty and the loss of exclusivity risks on semaglutide, the analyst tells investors in a research note. The firm says consensus estimates have rebased.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Employees Elect New Board Representatives Ahead of March AGM
- Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran
- Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Expands Weight-Loss Pill Manufacturing
- Novo Nordisk Details Progress of 2026 Share Buyback Programme
- Novo Nordisk downgraded to Neutral from Buy at Goldman Sachs